Takeda Rolls Out Ready-to-Use Low-IgA Immunoglobulin Therapy
CAMBRIDGE, Massachusetts, January 22, 2026 — Takeda Pharmaceutical Company Limited announced the U.S. availability of GAMMAGARD LIQUID ERC, the...
Biologic Therapy
Advertisement
Mabwell’s 9MW3011 Achieves Positive Phase III Results in Moderate-to-Severe Plaque Psoriasis
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
FDA Approves TREMFYA® for Pediatric Psoriasis and Psoriatic Arthritis
Horsham, Pa., Sept. 29, 2025 – The U.S. Food and Drug Administration (FDA) has granted approval for TREMFYA® (guselkumab)...
TREMFYA® Receives FDA Approval for Subcutaneous Induction in UC
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
Advertisement
